Company news
Aptorum Group Limited news in 2020
Aptorum Group Limited's news releases, calls and decks from 2020, newest first.
Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
December 20, 2020
Aptorum Group Limited Announces Results of 2020 Annual General Meeting of Shareholders
December 9, 2020
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 9, 2020
October 15, 2020
Aptorum Group Announces Closing of $9.0 Million Public Offering
October 1, 2020
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome
September 28, 2020
Aptorum Group Announces Pricing of $9.0 Million Public Offering
September 28, 2020
Aptorum Group Joins the BEAM Alliance To Combat Antimicrobial Resistance
September 7, 2020
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2020
August 31, 2020
Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential Tumor Types
August 31, 2020
Aptorum Group Announces Further Positive Data on ALS-4 against MRSA Wound Infection and MRSA Bacteraemia against Linezolid and Vancomycin Respectively in In Vivo Models
August 31, 2020
Aptorum Group Appoints Dr. Herman Weiss as CEO of microbiome-based platform Claves Life Sciences and Dr. Robbie Majzner as scientific advisor to SACT-1 drug for Neuroblastoma and others
August 19, 2020
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
March 29, 2020
Aptorum Group Collaborates with Covar Pharmaceuticals To Investigate at Least 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT™ Platform and Acticule Infectious Disease Platform
March 29, 2020
Aptorum Group Announces Closing of $10 Million Registered Direct Offering of Class A Ordinary Shares and Warrants
February 27, 2020
Aptorum Group Announces Pricing of $10 Million Registered Direct Offering
February 25, 2020
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
February 23, 2020
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
February 9, 2020
Aptorum Group Announces Further Positive Data For Its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate For The Treatment of Infections Caused By Staphylococcus Aureus and On Track Targeted For IND Submission in H2 2020
February 9, 2020